Bill Neidermyer, Ph.D., is a Senior Scientist at Skylark Bio working to advance the company’s mission to deliver transformative AAV-based genetic medicines. As one of the original members of Skylark Bio’s founding team in February of 2021, Dr. Neidermyer helped build the company’s internal AAV platform by designing novel AAV constructs, setting up in-house vector production, and leading the development of analytical assays to position Skylark for rapid program progression. He currently works to drive CMC manufacturing, assay development, and supply chain logistics.

Prior to joining Skylark Bio, Dr. Neidermyer helped establish the internal AAV platform and quality systems at Ally Therapeutics. He also brings research experience from laboratories studying preclinical HIV vaccines and from the NIH. Dr. Neidermyer earned his Ph.D. in Virology from Harvard University where he studied how viruses modulate cellular gene expression and his Bachelor’s in Molecular Biology from Colgate University. He is excited to combine his knowledge of cellular gene expression and molecular virology to bring innovative gene therapies to patients.